Evidence mapPaperPMID 4031063Full record

ArticleThe Journal of clinical investigation1985

Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, intermediate density lipoproteins, and low density lipoproteins.

W F Beltz, Y A Kesäniemi, B V Howard, S M Grundy

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 1985. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 98 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Causes and Consequences of Hypertriglyceridemia.Frontiers in endocrinology · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

W F Beltz
Y A Kesäniemi
B V Howard
S M Grundy
The University of Texas Southwestern Medical Center · US

Funding

TRANSCRIPTIONAL CONTROL OF GENES INVOLVED IN LDL MODIFICATION AND CATABOLISMP50HL014197 · UNIVERSITY OF CALIFORNIA SAN DIEGO · 1985 to 1997
METABOLISM OF APOLIPOPROTEIN B IN MANR01HL029252 · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · 1985 to 1987
CAUSES &TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIAR37HL029252 · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · 1987 to 1996
NHLBI NIH HHS HL-14197NHLBI NIH HHS HL-29252
6 · The paper itself

Abstract

To quantify more precisely the metabolism of apolipoprotein B (apo B) in human beings, an integrated model was developed for the analysis of the isotope kinetics of apo B in very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), and low density lipoproteins (LDL). The experimental basis for model development was a series of 30 triple-isotope studies in which patients received autologous 131I-VLDL, 125I-IDL, and [3H]glycerol as a precursor of VLDL triglycerides. The currently proposed model contains the following components: (a) a VLDL delipidation cascade that has a variable number of subcompartments, (b) a slowly catabolized pool of VLDL, (c) an IDL compartment consisting of two closely connected subcompartments, one of which is outside the immediate circulation, and (d) a two-compartment subsystem for LDL. Because mass data indicate that not all VLDL were converted to LDL, the model allows for irreversible removal of apo B from VLDL (or IDL) subsystems. It accounts for apparent "direct" input of LDL by postulating an early, rapidly metabolized compartment of VLDL that is converted directly to IDL. The model appears to be consistent with specific activity curves from the current triple-isotope studies and with present concepts of lipoprotein physiology; it also can be used to quantify pathways of lipoprotein apo B transport in normal and abnormal states.

Indexed as

Apolipoproteins BBiological TransportHumansKineticsLipoproteinsLipoproteins, IDLLipoproteins, LDLLipoproteins, VLDLModels, BiologicalTriglyceridesApolipoproteins BLipoproteinsLipoproteins, IDLLipoproteins, LDLLipoproteins, VLDLTriglyceridesvery low density lipoprotein triglyceride

Identifiers

PMID4031063
PMCPMC423863
OpenAlexW2126724716

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.